Vital Signs

Showing 31-40 of 307

This issue of Vital Signs, released on December 5, 2014, discusses LabCorps acquisition of Covance, MedImmunes acquisition of Definiens, the Google X cancer and heart attack detector, and VWRs acquisition of two fluid handling components companies.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs, released on November 6, 2014, discusses Immucors collaboration with Sirona Genomics, Becton Dickinsons acquisition of GenCell Biosystems, and an update on the Ebola virus.

USD 500.00

USD 375.00 save 25 %

As with every cardiology tradeshow today, the show floor of the 2014 European Society of Cardiology (ESC) Congress in Barcelona (Aug. 30-Sept. 3) reserved quite a significant presence for medical imaging. This comes as no surprise, since imaging and informatics continues to reaffirm their role as an important driving force for advancing several are...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on October 3, 2014, discusses Merck KGaAs acquisition of Sigma-Aldrich, highlights from the 2014 AACC Meeting, Abbotts CE Mark for FreeStyle® Libre, laboratory developed test (LDT) regulations, and the sale of Fortis Healthcares Singapore subsidiary, RadLink-Asia Pte Ltd, and its arm, RadLink Singapore.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on September 3, 2014, discusses Thermo Fisher Scientifics divestment of laboratory equipment company Cole-Parmer to GTCR, the increasing use of large animal biotechnology in human health applications, the collaboration of Life Technologies and RainTree Oncology Services, the agreement between Ventana and Quintile...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biologys Series A funding round, Roches investment in Stratos Genomics, and Indias cap on drug prices.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogens Eloctate, Qiagens acquisition of Primera Dx, Roches acquisition of Genia Technologies, Cues at-home connected lab test, and the Credihealth Teen Clinic.

USD 450.00

USD 337.50 save 25 %

11 Jun 2014  |  North America

Vital Signs - Value Emerging as a New Currency in Medical Imaging Markets

Value Based Imaging

The concept of value-based imaging is certainly not new, but it has garnered considerable attention from the medical imaging community over the past few years. Confined until recently to the realm of thought leaders at luminary healthcare and advocacy organizations, the concept has gained wide momentum in the past year. Since medical imaging repres...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.

USD 450.00

USD 337.50 save 25 %

Showing 31-40 of 307